Market Overview

Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant's 2025 Goals

Share:
Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant's 2025 Goals

Pfizer Inc. (NYSE: PFE) shares declinded Monday after the company said that a Phase 3 breast cancer treatment study — known as "PALLAS" — is unlikely to hit the primary goal, citing efficacy and futility analysis done by an Independent Data Monitoring Committee.  The study evaluated Ibrance, one of its drugs, with standard adjuvant endocrine therapy in HR+ and HER- in order to test its effectiveness in treating early stage breast cancer.

The Pfizer Analyst

Cantor Fitzgerald analyst Louise Chen maintained an Overweight rating on Pfizer shares with a $53 price target. 

The Pfizer Thesis

The adjuvant opportunity for the breast cancer drug Ibrance is being viewed by investors as a key growth driver for Pfizer, Chen said in a Friday note. (See her track record here.)

The analyst said she expects the consensus sales estimate for Ibrance to come down to reflect a lower opportunity.

Pfizer had earlier said the adjuvant opportunity could double the eligible patient population for Ibrance, she said.

Ibrance is already approved in the U.S. for treating adult patients with HR+, HER- advanced breast cancer.

The Street projects that Ibrance sales will grow from $5 billion in 2019 to $11.5 billion by 2025, Chen said.

The analyst estimates worldwide Ibrance sales of $8.6 billion in 2025, assuming a 33% probability of success for the PALLAS and PENELOPE-B studies.

The PENELOPE-B study is on track to readout by the second half of 2020, she said. 

Yet with mixed data from the PALLAS and a Phase 2 study dubbed PALLET, expectations for the PENELOPE-B study will be modest, Chen said. 

Despite the disappointing news, Pfizer said it remains confident in its ability to deliver on its goal of at least 6% revenue CAGR through 2025, according to Cantor Fitzgerald. 

This assertion will hardly be credible to investors, the analyst said. 

"We think PFE's ability to hit its CAGR target will depend more than ever on its ability to deliver strong growth from its in-line portfolio as well as contributions from the pipeline/new product launches." 

PFE Price Action

At last check, Pfizer shares were sliding 6.69% to $35.58.

Related Links:

The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

Moderna Doses First Participants In Phase 2 Study Of Coronavirus Vaccine

Photo by Coolcaesar via Wikimedia

Latest Ratings for PFE

DateFirmActionFromTo
Jun 2020SVB LeerinkInitiates Coverage OnMarket Perform
Jun 2020JP MorganMaintainsNeutral
Apr 2020BarclaysMaintainsEqual-Weight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!

Posted-In: Cantor Fitzgerald ibranceAnalyst Color Biotech Price Target Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
SOLOAegis CapitalAssumes4.0
TSLAJP MorganMaintains295.0
CVNAWedbushMaintains125.0
PFSICredit SuisseMaintains46.0
PMTCredit SuisseMaintains22.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com